Angiogenesis Impairment in Diabetes: Role of Methylglyoxal-Induced Receptor for Advanced Glycation Endproducts, Autophagy and Vascular Endothelial Growth Factor Receptor 2

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Liu, Hongtao ^a   Yu, Shujie ^a   Zhang, Hua ^a   Xu, Jian ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BECLIN 1; BIOLOGICAL MARKER; GLYOXALASE; GLYOXALASE 1; LC3B PROTEIN; MESSENGER RNA; METHYLGLYOXAL; PEROXYNITRITE; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DIABETES MELLITUS; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; WESTERN BLOTTING;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BLOTTING, WESTERN; CATTLE; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; DIABETES MELLITUS; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; PYRUVALDEHYDE; REAL-TIME POLYMERASE CHAIN REACTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA; MUS;

EID: 84867041125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046720     Document Type: Article

References (85)

1. Carmeliet P, (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
2. Duh E, Aiello LP, (1999) Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48: 1899-1906.
3. Leeper NJ, Cooke JP, (2011) MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation 123: 236-238.
4. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, et al. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6: 1677-1683.
5. Takahashi T, Shibuya M, (1997) The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14: 2079-2089.
6. Mac Gabhann F, Popel AS, (2008) Systems biology of vascular endothelial growth factors. Microcirculation 15: 715-738.
7. Matsumoto T, Claesson-Welsh L, (2001) VEGF receptor signal transduction. Sci STKE 2001: re21.
8. Simons M, (2005) Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 46: 835-837.
9. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
10. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
11. Shibuya M, (2006) Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13: 63-69.
12. Tiwari A, Jung JJ, Inamdar SM, Brown CO, Goel A, et al. (2011) Endothelial Cell Migration on Fibronectin Is Regulated by Syntaxin 6-mediated {alpha}5{beta}1 Integrin Recycling. J Biol Chem 286: 36749-36761.
13. Manickam V, Tiwari A, Jung JJ, Bhattacharya R, Goel A, et al. (2011) Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood 117: 1425-1435.
14. Bruns AF, Herbert SP, Odell AF, Jopling HM, Hooper NM, et al. (2010) Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic 11: 161-174.
15. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, et al. (2006) VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 108: 2624-2631.
16. Waltenberger J, (2009) VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 37: 1167-1170.
17. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, et al. (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105: 373-379.
18. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, et al. (2005) Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 46: 827-834.
19. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, et al. (2003) Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 31: 401-418.
20. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ, (2003) Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 31: 1423-1425.
21. Baynes JW, Thorpe SR, (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9.
22. Yan SF, Ramasamy R, Schmidt AM, (2008) Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4: 285-293.
23. Kalapos MP, (1999) Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol Lett 110: 145-175.
24. Giacco F, Brownlee M, (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.
25. Thornalley PJ, (2003) Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31: 1343-1348.
26. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, et al. (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101: 1142-1147.
27. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, et al. (2011) Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 286: 1374-1380.
28. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, et al. (2001) Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 60: 2351-2359.
29. Teixeira AS, Andrade SP, (1999) Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 64: 655-662.
30. Ahmed U, Dobler D, Larkin SJ, Rabbani N, Thornalley PJ, (2008) Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro. Ann N Y Acad Sci 1126: 262-264.
31. Tamarat R, Silvestre JS, Huijberts M, Benessiano J, Ebrahimian TG, et al. (2003) Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A 100: 8555-8560.
32. Coultas L, Chawengsaksophak K, Rossant J, (2005) Endothelial cells and VEGF in vascular development. Nature 438: 937-945.
33. Xu J, Wu Y, Song P, Zhang M, Wang S, et al. (2007) Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116: 944-953.
34. Xu J, Wang S, Wu Y, Song P, Zou MH, (2009) Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension. Hypertension 54: 625-632.
35. Xu J, Xie Z, Reece R, Pimental D, Zou MH, (2006) Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 26: 2688-2695.
36. Shibata M, Lu T, Furuya T, Degterev A, Mizushima N, et al. (2006) Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem 281: 14474-14485.
37. Liu HT, Li WM, Xu G, Li XY, Bai XF, et al. (2009) Chitosan oligosaccharides attenuate hydrogen peroxide-induced stress injury in human umbilical vein endothelial cells. Pharmacol Res 59: 167-175.
38. Jiang H, Weyrich AS, Zimmerman GA, McIntyre TM, (2004) Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. J Biol Chem 279: 55905-55913.
39. Nagata D, Mogi M, Walsh K, (2003) AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 278: 31000-31006.
40. Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, et al. (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115: 3843-3851.
41. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, et al. (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 105: 3374-3379.
42. Small GR, Hadoke PW, Sharif I, Dover AR, Armour D, et al. (2005) Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci U S A 102: 12165-12170.
43. Suttisansanee U, Lau K, Lagishetty S, Rao KN, Swaminathan S, et al. (2011) Structural variation in bacterial glyoxalase I enzymes: investigation of the metalloenzyme glyoxalase I from Clostridium acetobutylicum. J Biol Chem 286: 38367-38374.
44. Rabbani N, Thornalley PJ, (2011) Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 22: 309-317.
45. Kraus JL, Pernice P, Ponce C, (1988) Inhibition of glyoxalase I by various clinically used anticancer drugs. Res Commun Chem Pathol Pharmacol 59: 419-422.
46. Bartyik K, Turi S, Orosz F, Karg E, (2004) Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukaemia. Eur J Cancer 40: 2287-2292.
47. Levine B, Kroemer G, (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
48. Murdaca J, Treins C, Monthouel-Kartmann MN, Pontier-Bres R, Kumar S, et al. (2004) Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. J Biol Chem 279: 26754-26761.
49. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
50. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. (2004) The role of autophagy during the early neonatal starvation period. Nature 432: 1032-1036.
51. Xu J, Zou MH, (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120: 1266-1286.
52. Chen Y, Gibson SB, (2008) Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy 4: 246-248.
53. Pacher P, Beckman JS, Liaudet L, (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
54. Szabo C, Ischiropoulos H, Radi R, (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680.
55. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, et al. (2010) Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107: 106-116.
56. Cai H, (2005) Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 68: 26-36.
57. Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO, (2011) The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem 286: 44045-44056.
58. Jopling HM, Odell AF, Hooper NM, Zachary IC, Walker JH, et al. (2009) Rab GTPase regulation of VEGFR2 trafficking and signaling in endothelial cells. Arterioscler Thromb Vasc Biol 29: 1119-1124.
59. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC, (2011) VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 6: e25668.
60. Martin A, Komada MR, Sane DC, (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23: 117-145.
61. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T, (2008) Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14: 487-495.
62. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, et al. (2003) Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 52: 2805-2813.
63. Naito Y, Takagi T, Oya-Ito T, Okada H, Suzuki T, et al. (2009) Impaired gastric ulcer healing in diabetic mice: role of methylglyoxal. J Physiol Pharmacol 60Suppl 7: 123-130.
64. Luo B, Soesanto Y, McClain DA, (2008) Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol 28: 651-657.
65. Devi MS, Sudhakaran PR, (2011) Differential modulation of angiogenesis by advanced glycation end products. Exp Biol Med (Maywood) 236: 52-61.
66. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, et al. (2007) Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101: 948-956.
67. Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, et al. (2011) Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta. Blood 118: 2015-2026.
68. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, et al. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465: 487-491.
69. Smadja DM, Bieche I, Helley D, Laurendeau I, Simonin G, et al. (2007) Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6). J Cell Mol Med 11: 1149-1161.
70. Zhang H, He Y, Dai S, Xu Z, Luo Y, et al. (2008) AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Invest 118: 3904-3916.
71. Kuczynski EA, Patten SG, Coomber BL, (2011) VEGFR2 Expression and TGF-beta Signaling in Initial and Recurrent High-Grade Human Glioma. Oncology 81: 126-134.
72. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, et al. (2003) Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 14: 334-347.
73. Jopling HM, Howell GJ, Gamper N, Ponnambalam S, (2011) The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochem Biophys Res Commun 410: 170-176.
74. Ryter SW, Lee SJ, Smith A, Choi AM, (2010) Autophagy in vascular disease. Proc Am Thorac Soc 7: 40-47.
75. Meijer AJ, Codogno P, (2008) Autophagy: a sweet process in diabetes. Cell Metab 8: 275-276.
76. Gonzalez CD, Lee MS, Marchetti P, Pietropaolo M, Towns R, et al. (2011) The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 7: 2-11.
77. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S, (2007) Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109: 4793-4802.
78. Ramakrishnan S, Nguyen TM, Subramanian IV, Kelekar A, (2007) Autophagy and angiogenesis inhibition. Autophagy 3: 512-515.
79. Bansode RR, Ahmedna M, Svoboda KR, Losso JN, (2011) Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide. Int J Biol Sci 7: 629-644.
80. Lee SJ, Kim HP, Jin Y, Choi AM, Ryter SW, (2011) Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy 7: 829-839.
81. Rask-Madsen C, King GL, (2008) More sugar, less blood vessels: another piece in the puzzle of increased cardiovascular risk in diabetes. Arterioscler Thromb Vasc Biol 28: 608-610.
82. Eichmann A, Simons M, (2012) VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 24: 188-193.
83. Yamagishi SI, Maeda S, Matsui T, Ueda S, Fukami K, et al. (2011) Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta.
84. Mendez JD, Xie J, Aguilar-Hernandez M, Mendez-Valenzuela V, (2010) Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 341: 33-41.
85. Kim W, Hudson BI, Moser B, Guo J, Rong LL, et al. (2005) Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1043: 553-561.